Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Delphine Gaufreteau

Jean-Marc Plancher

Sabine Kolczewski

Theodor Stoll

Hans Hilpert

Roland Humm

Thorsten Muser

Remy Halm

Matthias Heinrich Nettekoven

Bernd Kuhn

Olivier Roche

Jens-Uwe Peters

Wolfgang Haap

Thomas Luebbers

David Banner

Guido Hartmann

Tadakatsu Takahashi

Lilli Anselm

Sebastien Schmitt

Jean-Baptiste Blanc

Beat Spinnler

Sébastien Schmitt

The present invention is concerned with indolin-2-one derivatives of general formula wherein the substituents are defined in claim The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.

Indolin-2-one derivatives

The present invention is concerned with indolin-2-one derivatives of general formula wherein   The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co morbid epilepsy.

The present invention is concerned with indolin-2-one derivatives of general formula    The compounds may be used in the treatment of CNS diseases related to positive (psychosis) and negative symptoms of schizophrenia, substance abuse, alcohol and drug addiction, obsessive-compulsive disorders, cognitive impairment, bipolar disorders, mood disorders, major depression, treatment resistant depression, anxiety disorders, Alzheimer's disease, autism, Parkinson's disease, chronic pain, borderline personality disorder, neurodegenerative disease, sleep disturbances, chronic fatigue syndrome, stiffness, inflammatory disease, asthma, Huntington's disease, ADHD, amyotrophic lateral sclerosis, effects in arthritis, autoimmune disease, viral and fungal infections, cardiovascular diseases, ophthalmology and inflammatory retinal diseases and balance problems, epilepsy and neurodevelopmental disorders with co-morbid epilepsy.

The invention relates to a compound of formula (I) wherein A, B, D and Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Cyclic amides

The present invention relates to compounds of formula I wherein Rand Rare as defined in the description and claims, and pharmaceutically acceptable salts thereof. The compounds are useful for the treatment and/or prevention of diseases which are associated with the modulation of H3 receptors.

Cyclohexyl derivatives

Growing community of inventors

Kembs, France

Delphine Gaufreteau